Fast and accurate evaluation of environmental chemical toxicity currently is challenged by the high cost and low-throughput nature of traditional toxicity testing methods and the large number of environmental chemicals that need to be evaluated \[[@r7]; [@r20]; National Research Council (NRC) 2007\]. In response to these challenges, three government agencies---the U.S. Environmental Protection Agency (EPA), the National Toxicology Program (NTP), and the National Institutes of Health (NIH) Chemical Genomics Center (NCGC)---launched a collaborative initiative, the Tox21 program ([@r4]; [@r20]), and were recently joined by the U.S. Food and Drug Administration. The goal of this effort is to employ a broad spectrum of *in vitro* assays to use high-throughput screening (HTS) methods to screen a large number of environmental chemicals for their potential to disturb biological pathways that may result in toxicity. The data generated will be used to derive biological and chemical profiles that could serve as the basis for prioritization of chemicals for further toxicological evaluation ([@r30]), act as predictive surrogates for *in vivo* toxicity end points ([@r18]), and generate testable hypotheses on mechanism of toxicity ([@r14]; [@r38]).

Nuclear receptors (NRs) are a family of transcription factors that are important regulators of metabolism, differentiation, apoptosis, and cell cycle progression. The transcriptional activities of NRs are regulated by small, lipophilic molecules ([@r10]), including pharmaceutical agents and chemicals in the environment, and their altered function has been related to a number of diseases ([@r22]; [@r35]; [@r36]). For example, interaction of a variety of pesticides and other industrial chemicals with the estrogen and androgen NRs has been linked to a number of adverse health consequences, including birth defects, impaired reproductive capacity, developmental neurotoxicity, and certain cancers ([@r5]). Because the mechanism of action leading to such toxicities is directly linked to chemicals binding to NRs, they make an ideal starting point for using HTS tools to characterize toxicity pathways as envisioned by the NRC (2007). As a Tox21 proof-of-concept study, we screened an environmentally relevant library consisting of approximately 3,000 chemicals against a panel of 10 human NRs---the androgen receptor (AR), estrogen receptor α (ERα), farnesoid X receptor (FXR), glucocorticoid receptor (GR), liver X receptor β (LXRβ), peroxisome proliferator-activated receptor γ (PPARγ), peroxisome proliferator-activated receptor δ (PPARδ), retinoid X receptor α (RXRα), thyroid hormone receptor β (TRβ), and vitamin D receptor (VDR)---in a quantitative high-throughput screening (qHTS) format ([@r16]; [@r37]). In this format, a concentration--response curve is generated for every compound to identify both potential agonists and antagonists.

The systematic profiling of a large set of environmental chemicals such as the Tox21 compound collection against the panel of 10 NRs is the initial step toward identifying substances with endocrine-disrupting and other NR-mediated toxicity potential. We examined the interactions for concordance with expected findings for a small number of well-characterized NR ligands, for reproducibility across duplicate chemicals in the library, for biological profiles by clustering activities across NRs based on sequence homology of their ligand-binding domains (LBDs), and by phenotypic clustering to look for structure--activity relationships (SARs). The results demonstrate the feasibility of HTS to identify the potential for environmentally relevant chemicals to interact with key toxicity pathways related to human disease induction.

Materials and Methods
=====================

*Compound collection.* The current Tox21 compound collection consists of 2,870 compounds: 1,408 provided by the NTP ([@r39]) and 1,462 provided by the U.S. EPA ([@r15]; [@r19]). The structures and annotations of these compounds are publicly available ([@r13]; [@r27], [@r28]). The compounds were dissolved in dimethyl sulfoxide (DMSO) and plated in 1,536-well plate format at 14 or 15 concentrations ranging from 0.1 μM to 20 mM. See Supplemental Material for more details (doi:10.1289/ehp.1002952).

β*-Lactamase reporter gene assay and qHTS.* GeneBLAzer β-lactamase (*bla*) HEK 293T cell lines that constitutively co-express a fusion protein composed of the LBDs of related human NRs coupled to the DNA-binding domain of the yeast transcription factor GAL and cell culture reagents were obtained from Invitrogen (Carlsbad, CA). See Supplemental Material for more details (doi:10.1289/ehp.1002952).When activated, these fusion proteins then stimulate *bla* reporter gene expression. Compound formatting and qHTS were performed as described previously ([@r38]). Briefly, the *bla* cells with different NRs were dispensed in 1,536-well plates for screening. After cells were incubated for 5--6 hr, compounds at 14 or 15 concentrations from the NTP and U.S. EPA collections were transferred to the assay plate with the final concentrations ranging from 0.5 nM to 92 μM. The plates were incubated for 16--18 hr at 37°C before detection mix was added, and the plates were then incubated again at room temperature for 1.5--2 hr. Fluorescence intensity (405 nm excitation, 460- and 530-nm emission) was measured using an Envision plate reader (PerkinElmer, Shelton, CT). Data were expressed as the ratio of 460-nm to 530-nm emissions. The assay performance was assessed by plate statistics (signal-to-background ratio, Z´-factor, coefficient of variation) ([@r40]) (see Supplemental Material, [Table 2](#t2){ref-type="table"}).

###### 

NR ligands and their observed assay activities.

  NR ligand name                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Known NR activity*a*   NR assay*b*        Observed phenotype*c*   Observed EC~50~ or IC~50~ (μM)*d*                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ------------------ ----------------------- ----------------------------------- -- ----------- -- ----------
  Danazol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            AR agonist                                 AR agonist                             Activator      0.06
  17α-Hydroxyprogesterone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            AR agonist                                 AR agonist                             Activator      0.002
  Progesterone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       AR agonist                                 AR agonist                             Activator      0.06
  Corticosterone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AR agonist                                 AR agonist                             Activator      0.22
  Cyproterone acetate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                AR antagonist                              AR antagonist                          Inhibitor      15.85
  Flutamide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          AR antagonist                              AR antagonist                          Inhibitor      31.62
  Mifepristone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       AR antagonist                              AR antagonist                          Inhibitor      2.00
  Nilutamide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         AR antagonist                              AR antagonist                          Inhibitor      12.59
  Diethylstilbestrol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ERα agonist                                ERα agonist                            Activator      \< 0.001
  β-Estradiol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ERα agonist                                ERα agonist                            Activator      \< 0.001
  1,3,5-tris(4-Hydroxyphenyl)-4-propyl-1H-pyrazole                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ERα agonist                                ERα agonist                            Activator      0.10
  4-Hydroxytamoxifen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ERα antagonist                             ERα antagonist                         Inhibitor      0.07
  Raloxifene hydrochloride                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ERα antagonist                             ERα antagonist                         Inhibitor      0.03
  Tamoxifen citrate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ERα antagonist                             ERα antagonist                         Inhibitor      8.91
  Lithocholic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   FXR agonist                                FXR agonist                            Activator      22.39
  Beclomethasone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     GR agonist                                 GR agonist                             Activator      0.04
  Betamethasone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      GR agonist                                 GR agonist                             Activator      0.09
  Dexamethasone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      GR agonist                                 GR agonist                             Activator      0.02
  Hydrocortisone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     GR agonist                                 GR agonist                             Activator      0.08
  Triamcinolone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      GR agonist                                 GR agonist                             Activator      0.11
  Cholesterol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        LXR agonist                                LXRβ agonist                           Activator      39.81
  TO-901317                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          LXR agonist                                LXRβ agonist                           Activator      0.25
  Fmoc-l-leucine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     PPARγ agonist                              PPARγ agonist                          Activator      11.22
  Ciglitizone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        PPARγ agonist                              PPARγ agonist                          Activator      1.41
  GW1929                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             PPARγ agonist                              PPARγ agonist                          Activator      0.002
  Troglitazone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       PPARγ agonist                              PPARγ agonist                          Activator      0.13
  DRF 2519                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           PPARγ agonist                              PPARγ agonist                          Activator      0.10
  BADGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              PPARγ antagonist                           PPARγ antagonist                       Inhibitor      50.12
  GW9662                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             PPARγ antagonist                           PPARγ antagonist                       Inhibitor      12.59
  2-Bromohexadecanoic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           PPARδ agonist                              PPARδ agonist                          Activator      28.18
  GW0742                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             PPARδ agonist                              PPARδ agonist                          Activator      19.95
  l-165,041                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          PPARδ agonist                              PPARδ agonist                          Activator      0.09
  13-*cis*-Retinoic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             RAR agonist                                RXRα agonist                           Activator      0.25
  TTNPB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              RAR agonist                                RXRα agonist                           Activator      0.71
  AM-580                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             RARα agonist                               RXRα agonist                           Activator      0.62
  Retinoic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      RXR agonist                                RXRα agonist                           Activator      0.13
  3,3´,5-Triiodo-l-thyronine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         TR agonist                                 TRβ agonist                            Activator      \< 0.001
  Lithocholic acid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   VDR agonist                                VDR agonist                            Activator      22.39
  Abbreviations: BADGE, bisphenol A diglycidyl ether; RAR, retinoic acid receptor; TTNPB, (E)-4-\[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1 -propenyl\] benzoic acid. **a**NR activity of compound reported in literature. **b**The NR *bla* assay in which the compound was tested. **c**Activity observed for the compound when tested in the NR *bla* assay. **d**EC~50~ (agonist) or IC~50~ (antagonist) obtained for the compound when tested in the NR *bla* assay.                                                                                                                           

*qHTS data analysis.* Analysis of compound concentration--response data was performed as previously described ([@r16]). See Supplemental Material for more details (doi:10.1289/ehp.1002952). Briefly, raw plate reads for each titration point were first normalized relative to the positive control compound and DMSO-only wells and then corrected by applying an NCGC in-house pattern correction algorithm using compound-free control plates (i.e., DMSO-only plates) at the beginning and end of the compound plate stack. Concentration--response titration points for each compound were fitted to a four-parameter Hill equation ([@r12]), yielding concentrations of half-maximal activity (AC~50~) and maximal response (efficacy) values. Compounds were designated as class 1--4 according to the type of concentration--response curve observed ([@r16]). Curve classes are heuristic measures of data confidence, classifying concentration--responses on the basis of efficacy, the number of data points observed above background activity, and the quality of fit. To facilitate analysis, each curve class was combined with an efficacy cutoff and converted to a numeric curve rank such that more potent and efficacious compounds with higher quality curves were assigned a higher rank (see Supplemental Material, Table 4). Curve ranks should be viewed as a numeric measure of compound activity. Compounds that showed activation/inhibition in both the ratio and the 460-nm readouts were defined as activators/inhibitors. Among the activators/inhibitors, compounds with curve rank ≥ 5 or ≤ --5 in the ratio readout were further defined as active activators (agonists)/inhibitors (antagonists). Compounds with curve rank 0 (curve class 4) in both the ratio and 460-nm readouts were defined as inactive, and compounds with other phenotypes were defined as inconclusive. Curve rank, potency, and efficacy data generated on all compounds and assays can be downloaded from [@r13].

Results
=======

An initial evaluation of assay performance showed that the assays behaved as expected in terms of biological activity of known agonists and antagonists included as positive control compounds in the screening libraries. The Tox21 compound collection contains a set of 54 known NR ligands assembled by Sigma (St. Louis, MO) (Sigma 2007). [Table 1](#t1){ref-type="table"} lists the ligands with known interactions with NRs included in the present study and their activities observed \[phenotype and half-maximal effective concentration (EC~50~) or inhibitory concentration (IC~50~)\] in the corresponding NR assays. We positively identified all of these known ligands with our assays, with expected potencies confirming the utility of these NR assays. Some of the apparent actives identified from the LXRβ assays indicated a potential problem with the LXRβ cell line (data not shown). We thus excluded data from these assays from further analysis.

###### 

Compound reproducibility definitions.

  Replicate no. 1                                                                                                                                                                                                                 Replicate no. 2   Call            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ------------ -- ----------------
  Agonist*a*                                                                                                                                                                                                                                        Agonist         Active match
  Antagonist*b*                                                                                                                                                                                                                                     Antagonist      Active match
  Inactive*c*                                                                                                                                                                                                                                       Inactive        Inactive match
  Agonist                                                                                                                                                                                                                                           Inactive        Mismatch
  Inactive                                                                                                                                                                                                                                          Agonist         Mismatch
  Antagonist                                                                                                                                                                                                                                        Inactive        Mismatch
  Inactive                                                                                                                                                                                                                                          Antagonist      Mismatch
  Agonist                                                                                                                                                                                                                                           Antagonist      Mismatch
  Antagonist                                                                                                                                                                                                                                        Agonist         Mismatch
  Other*d*                                                                                                                                                                                                                                          Other           Inconclusive
  **a**Compound with curve rank ≥ 5. **b**Compound with curve rank ≤ --5. **c**Compound with a curve rank of 0. **d**"Other" includes compounds that showed inconclusive activities with nonzero curve ranks between --4 and 4.                                     

[Figure 1A,B](#f1){ref-type="fig"} shows the distributions of compound activity outcomes in the agonist- and antagonist-mode assays, respectively. In general, more compounds were active in the antagonist-mode assays than in the agonist-mode assays ([Figure 1C](#f1){ref-type="fig"}), in which cytotoxicity might be playing a role. The percentage of compounds classified as active ranged from 0.4% (FXR) to 3.2% (ERα) in the agonist-mode assays and from 3.3% (PPARδ) to 10.9% (AR) in the antagonist-mode assays. When we excluded compounds identified as potentially autofluorescent and/or cytotoxic (see below for criteria applied), the fractions of apparent activators and inhibitors decreased for both the agonist- and antagonist-mode assays (data not shown), but the number of apparent active compounds remained larger in the antagonist-mode assays, although by a smaller margin.

![Distributions of compound activity outcomes in the agonist-mode (*A*) and antagonist-mode (*B*) NR assays. (*C*) Distribution of active agonists and antagonists.](ehp.1002952.g001){#f1}

*Compound reproducibility.* There were 130 compounds replicated in the U.S. EPA plate and 66 compounds in the NTP plate, and 416 compounds overlapped between the U.S. EPA and the NTP plates. We calculated compound reproducibility for all NR assays in both agonist and antagonist mode using the ratio readout. We first defined each compound replicate as an agonist, an antagonist, inconclusive, or inactive based on its curve rank \[for details, see Supplemental Material, Table 4 (doi:10.1289/ehp.1002952)\]. We then made three types of reproducibility calls (match, mismatch, and inconclusive) based on the concordance of each replicate ([Table 2](#t2){ref-type="table"}). Overall, the intraplate replicates showed slightly better reproducibility (88.6%) than did interplate replicates between the U.S. EPA and NTP libraries (85.5%). Both mismatch (4.1%) and inconclusive (10.4%) rates were slightly higher for the interplate than for the intraplate replicates (3.5% mismatch and 7.9% inconclusive). Variations in compound reproducibility were assay dependent ([Figure 2](#f2){ref-type="fig"}). The overall matching rate, counting both intra- and interplate replicates, ranged from 97.7% (GR agonist) to 74.2% (RXRα agonist); mismatch rates ranged from 0.3% and 0.5% (GR and FXR agonist mode) to 9.0% (RXRα agonist), and inconclusive rates ranged from 2.0% (GR agonist) to 16.8% (RXRα agonist).

![Intralibrary (*A*) and interlibrary (*B*) compound reproducibility across different NR assays. Intralibrary reproducibility is calculated by comparing the activity of copies of each compound replicated within the U.S. EPA or NTP compound library. Interlibrary reproducibility is calculated by comparing the activity of the NTP copy and U.S. EPA copy of each compound presented in both the U.S. EPA and NTP libraries.](ehp.1002952.g002){#f2}

The reproducibility of an assay is a good indicator of assay performance and quality. To generate a single measure of reproducibility so that all assays could be easily compared, we scored all NR assays (2× % active match + % inactive match -- % inconclusive -- 2× % mismatch) and ranked them by this score, sorted in descending order ([Table 3](#t3){ref-type="table"}). We calculated the reproducibility score in a way such that assays with higher concordance rates and lower mismatch rates would be ranked higher. We assigned more weight to active matches and mismatches because we derived these results from more reliable concentration--response curves and to account for the overall low active rate. We assigned each assay an arbitrary grade: A (score, ≥ 90%), B (≥ 80% to 90%), C (≥ 70% to 80%), or D (\< 70%), with A being the highest-quality assays in terms of reproducibility and D the lowest. The grades are meant only to serve as a guide for assay prioritization. With this ranking scheme, we ranked the GR and FXR agonist-mode assays as the best-performing assays and the RXRα agonist-mode assay as the worst performing, with the lowest data reproducibility. The agonist-mode assays performed better overall than did the antagonist-mode assays---among the top 50% performing assays, six were agonist-mode assays and only three were antagonist-mode assays. The top five assays were all agonist mode. This outcome was not entirely unexpected because the antagonist-mode assays all required the pre-addition of nonsaturating levels of an agonist compound to stimulate the receptor signal before test compounds could be screened, which introduces an extra source of variance.

###### 

NR assays ranked by their compound reproducibility.

  Assay                                                                                                                Mismatch (%)   Inconclusive (%)   Match (%)   Reproducibility score (%)   Assay grade*a*                       
  -------------------------------------------------------------------------------------------------------------------- -------------- ------------------ ----------- --------------------------- ---------------- ------ -- ------ -- ---
  GR agonist                                                                                                                          0.3                            2.0                                          97.7      98.0      A
  FXR agonist                                                                                                                         0.5                            2.1                                          97.4      95.8      A
  TRβ agonist                                                                                                                         1.1                            2.3                                          96.6      94.8      A
  VDR agonist                                                                                                                         1.1                            3.1                                          95.8      91.2      A
  PPARδ agonist                                                                                                                       1.6                            6.4                                          92.0      91.2      A
  TRβ antagonist                                                                                                                      2.0                            6.0                                          92.0      89.4      B
  VDR antagonist                                                                                                                      2.9                            5.1                                          92.0      89.4      B
  FXR antagonist                                                                                                                      2.0                            10.0                                         88.1      89.1      B
  PPARγ agonist                                                                                                                       1.6                            7.5                                          90.8      86.1      B
  GR antagonist                                                                                                                       3.3                            9.6                                          87.1      85.1      B
  AR agonist                                                                                                                          2.8                            9.8                                          87.4      80.6      B
  PPARγ antagonist                                                                                                                    4.9                            11.4                                         83.7      77.5      C
  ERα agonist                                                                                                                         4.0                            9.8                                          86.2      76.9      C
  RXRα antagonist                                                                                                                     6.7                            8.3                                          85.0      76.8      C
  ERα antagonist                                                                                                                      4.8                            11.5                                         83.6      76.8      C
  PPARδ antagonist                                                                                                                    4.7                            11.6                                         83.7      71.6      C
  AR antagonist                                                                                                                       7.2                            15.4                                         77.5      67.2      D
  RXRα agonist                                                                                                                        9.0                            16.8                                         74.2      57.7      D
  **a**Assays with grade A were considered the highest quality assays in terms of reproducibility, and D the lowest.                                                                                                                  

*Using single-channel readouts of* bla *assays to assess autofluorescence and cytotoxicity.* Compound autofluorescence and cytotoxicity can interfere with assay readouts and produce artificial results, because fluorescent compounds could appear as activators and show up as false positives in agonist-mode assays, and cytotoxic compounds could appear as inhibitors because of reduced cell viability and show up as false positives in antagonist-mode assays. The green channel (530-nm readout) is the control channel of the *bla* assay. Increased or decreased fluorescence activity in this channel can be interpreted as an indicator of compound autofluorescence or cytotoxicity ([@r38]). Blue fluorescent compounds may not be detected in the 530-nm readout but could still interfere with the 460-nm readout, which is the blue, reporter-gene--dependent signal channel of the *bla* assay. Therefore, pan-activation in the blue channel across multiple NR assays would also indicate compound autofluorescence. We then identified a compound as autofluorescent if it showed activation in \> 10 of 20 agonist-mode assay readouts (counting both the 530-nm and 460-nm readouts separately) or if it showed activation in the 460-nm readout in more than four agonist-mode assays and was identified as fluorescent (activity \> 10% fluorescent control compound) at 460 nm in the autofluorescence spectra scans ([@r34]). Using these criteria, we identified 25 compounds (11 from NTP and 14 from U.S. EPA) as autofluorescent and excluded them from further analysis \[see Supplemental Material, Table 5 (doi:10.1289/ehp.1002952)\]. The criteria chosen for identifying autofluorescent compounds (as well as cytotoxic compounds) were empirical and were used to minimize false positives. Most of the compounds identified as autofluorescent by this method were well-known fluorophores, partially validating the approach. Further experimental studies are needed to fully confirm the apparent artifacts.

The cell viability assay has been widely used as a measure of compound cytotoxicity ([@r39]). We identified active compounds (non-class 4) identified by the cell viability assay in parental HEK 293 cells \[for a description of the cell viability assay, see Supplemental Material (doi:10.1289/ehp.1002952)\], or compounds that reduced activity in the 530-nm readout of more than four antagonist-mode assays, as cytotoxic and excluded them from further analysis of the antagonist-mode data. We identified a total of 323 compounds as potentially cytotoxic, 152 of which were from the NTP collection and 171 from the U.S. EPA collection (Supplemental Material, Table 6). Cytotoxicity interference is less of a concern for agonist-mode assays than for antagonist-mode assays because agonists that are cytotoxic at higher concentrations generate bell-shaped (inverted-U) concentration--response curves in the 460-nm channel. For more discussion on how activities in the 460-nm and 530-nm reads correlated with the cell viability assay results, see Supplemental Material, "Using single channel readouts of *bla* assays to assess cytotoxicity" and Supplemental Material, [Figure 1](#f1){ref-type="fig"}.

*Chemical genomics: compound activity-pattern similarity and NR LBD sequence homology.* The agonist-mode and the antagonist-mode NR assays were both hierarchically clustered using the correlation of the compound curve ranks (from the ratio readout) as the similarity metric. We excluded compounds identified as potentially autofluorescent from the clustering exercises and also excluded compounds identified as potentially cytotoxic from the clustering of the antagonist-mode assays. [Figure 3A,B](#f3){ref-type="fig"} shows results for agonist and antagonist mode, respectively. The agonist-data--based clustering of NRs ([Figure 3A](#f3){ref-type="fig"}) matched nearly perfectly with the NR LBD sequence homology \[[Figure 3C](#f3){ref-type="fig"}; see also Supplemental Material, [Figure 2](#f2){ref-type="fig"} (doi:10.1289/ehp.1002952)\] ([@r25]; [@r41]), where the agonist data clustering segregated the nine NRs into two major branches ([Figure 3A](#f3){ref-type="fig"}): the ER-like branch, with ERα, AR, and GR, and the thyroid hormone receptor (TR)-like branch, with RXRα and the rest of the NRs. The clustering again further divided the TR-like branch into two subgroups, one containing TRβ, FXR, and VDR and the other containing the two PPARs and RXRα. The only difference from the sequence clustering ([Figure 3C](#f3){ref-type="fig"}) was that PPARδ clustered more closely with RXRα than with PPARγ in the assay-data--based clustering ([Figure 3A](#f3){ref-type="fig"}).

![Comparison of the human NR LBD similarity and compound activity-pattern similarity. (*A*) and (*B*) Hierarchical clustering (Spotfire DecisionSite, version 8.2; Spotfire Inc., Cambridge, MA) of the agonist-mode (*A*) and antagonist-mode (*B*) NR assays using the correlation of the compound curve ranks (from the ratio readout) as the similarity metric, where each row represents a compound and each column represents an NR assay. The heat maps are colored based on compound activity: compounds that showed apparent activation (red) and inhibition (blue); less conclusive activators or inhibitors are colored a lighter shade of red or blue; inactive compounds are shown in white. (*C*) Phylogram of the LBDs of the nine human NRs tested. Amino acid sequences of the LBDs were downloaded from the PubMed protein database (PubMed 2010) and aligned using ClustalW2 (European Molecular Biology Laboratory--European Bioinformatics Institute 2009).](ehp.1002952.g003){#f3}

The antagonist-mode data--based clustering of the NRs ([Figure 3B](#f3){ref-type="fig"}) showed poor concordance with the NR LBD sequence homology ([Figure 3C](#f3){ref-type="fig"}). The ER-like subfamily members were segregated into two different branches, with ERα and GR in one branch and AR clustered into the other branch ([Figure 3B](#f3){ref-type="fig"}). This was surprising because GR is more closely related to AR than to ERα in terms of sequence similarity ([Figure 3C](#f3){ref-type="fig"}). The clustering grouped the TR-like subfamily into two clusters as well, with VDR, PPARδ, and PPARγ in one cluster and TRβ and FXR in the other ([Figure 3B](#f3){ref-type="fig"}). The two PPARs are the most closely related by sequence ([Figure 3C](#f3){ref-type="fig"}), but this was not reflected in the antagonist-mode--based phenotype clustering ([Figure 3B](#f3){ref-type="fig"}).

*SAR analysis.* We clustered all compounds in the NTP and U.S. EPA libraries based on structural similarity (2,048-bit Daylight fingerprints; Daylight Chemical Information Systems, Inc., Laguna Niguel, CA) using the self-organizing map (SOM) algorithm ([@r24]), yielding 336 clusters. Despite of the diversity in response \[for details, see Supplemental Material, "Structural diversity assessment of apparent NR agonists and antagonists," and Supplemental Material, [Figure 3](#f3){ref-type="fig"} (doi:10.1289/ehp.1002952)\], we identified 16 classes of compounds with consistent NR activity patterns by examining the activity patterns of compounds within each structure cluster. [Figure 4](#f4){ref-type="fig"} shows the structure scaffolds and NR activities of these compound classes. Among these are many known ligands or disruptors of NRs whose activities observed in our study was consistent with their known NR activities. Examples include the known ERα-active classes of compounds, such as the estradiol and tamoxifen analogs, parabens ([@r11]), bisphenyls (including bisphenol A, bisphenol B, and methoxychlor), and flavonoids; steroid hormones and analogs and flutamides with known AR activity; and corticosteroids with known GR activity. We also observed that subtle changes in structures of compounds belonging to the same class led to variations in their NR activity. For example, the class of steroid hormones was clustered into several subclasses based on their NR activity patterns, where the sex hormones appeared as agonists of AR and ERα and the corticosteroids showed activities mostly against AR and GR. Another example is the ERα activity of the flavonoids, where the isoflavones (e.g., genistein) were identified as more conclusive/potent ERα agonists than the normal flavonoids (e.g., kaempferol). Several classes of compounds, including the lactofen analogs ([@r2]) and dicarboximide fungicides ([@r21]), have been reported to induce liver toxicity. The lactofen analogs appeared primarily as PPARγ and AR antagonists, and the dicarboximide fungicides as AR antagonists, consistent with literature reports ([@r9]); however, the AR activity of the lactofen analogs has not been reported before. Of the chloroacetanilide herbicides, alachlor ([@r23]), and acetochlor ([@r31]) have been reported to have weak estrogenic effects, consistent with their weak activities observed in our ERα assays. However, we consistently identified this class of compounds as PPARγ antagonists in our NR assays as well. The NR activity of these compounds may be related to their liver toxicity.

![Example structure classes with consistent NR activity patterns or signatures. Compounds were clustered by structure similarity using the SOM algorithm. Compounds in the same cluster belong to the same structure class. The structure classes shown contain compounds with similar activity patterns as well. DDT, dichlorodiphenyltrichloroethane.](ehp.1002952.g004){#f4}

Discussion
==========

As Tox21 is moving from the pilot phase to the full production phase where a library of \> 10,000 compounds will be screened initially against suites of NRs and stress response pathways, selection of appropriate assays to be included is critical. A set of criteria needs to be established to determine the value and quality of an assay for inclusion into the Tox21 production phase. One approach is to use the existing data from the pilot-phase screens. Taking this approach, we have examined the NR profiling data generated from the pilot phase Tox21 collection of approximately 3,000 environmental chemicals in terms of data reliability, which can be measured by the level of variability/noise, dynamic range, and reproducibility, to assess potential challenges and propose strategies for data-driven assay prioritization. Having replicated compounds in the compound library was useful for assessing assay reproducibility. Assays ranked high on the reproducibility scale ([Table 3](#t3){ref-type="table"}) could be prioritized for the scaled-up screening of additional compound libraries. For assays that failed the data quality control criteria, which include the grade D assays and possibly the grade C assays listed in [Table 3](#t3){ref-type="table"}, replacement assays that measure the same biology (same NR in this case) need to be selected with alternative cell types, assay technologies (e.g., luciferase instead of *bla*), or readouts (e.g., luminescence instead of fluorescence).

Unlike the agonist-mode assays, in which the activities observed were nearly a perfect reflection of the NR LBD sequence phylogeny, the antagonist-mode phenotype clustering showed low concordance with sequence homology. One potential cause for this low concordance is that antagonists need not bind as perfectly as do agonists to the LBD to antagonize the receptor activity ([@r1]; [@r32]). Another possible explanation is that a compound may antagonize an NR via allosteric or noncompetitive effects instead of directly binding to the LBD of the NR ([@r17]), such that the LBD sequence would not contribute to the antagonist phenotype in these NR assays. Finally, cytotoxicity interference, not completely removed to avoid losing true antagonists, could be a playing a role. For example, tamoxifen, a well-known antagonist of the estrogen receptor, is also cytotoxic ([@r3]; [@r6]). In contrast, the agonist phenotype clustering of NRs showed good concordance with the sequence clustering results because cytotoxicity interference was minimal in the agonist (gain of signal) mode assays and binding to the LBD is probably necessary for a compound to activate an NR. These are further supported by the higher structure diversity observed for the apparent antagonists than the agonists. The lesson learned from this exercise is that we can use phenotype/chemical response data to infer LBD protein sequence/target relationships to a certain degree. The level of confidence depends on the noise level in the phenotype data. In the case of NRs, the agonist-mode data were more robust than the antagonist-mode data in inferring sequence relationships.

Regardless of the potential interference from compound autofluorescence and cytotoxicity, we showed these assays to be biologically relevant by positively identifying a set of known NR ligands built into the compound collection ([Table 1](#t1){ref-type="table"}). In addition, SAR analysis revealed a number of structural classes with consistent activity patterns ([Figure 4](#f4){ref-type="fig"}). These classes of compounds not only contain analogs of known NR ligands that further validated the utility of these assays, but also showed NR interactions not previously reported that warrant further toxicological evaluation because the SAR strengthens the validity of the observed activities. Several of these compound classes are known liver toxicants, the toxicity of which could be linked to their endocrine-disrupting potential, and as such, their NR activity patterns could serve as predictive signatures for their toxicity end point ([@r18]).

Conclusions
===========

Our analyses of the NR profiling data indicate that this is a valuable data set for generating hypotheses and establishing metrics for assay prioritization, and that we can strategically identify and reduce interpretive interference from assay artifacts. Moreover, LBD sequence and compound SAR analyses provide support to the utility of these qHTS assays in their ability to identify known endocrine-disrupting environmental chemicals and revealed classes of chemicals with activity patterns that could serve as bases for in-depth toxicological testing prioritization and provide clues for toxicity mechanism interpretation.
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=====================
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Click here for additional data file.
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